The Discovery Process
TScan’s proprietary discovery process identifies the natural targets of T cell receptors derived from patient tumors to create meaningful TCR therapies
Residing in the tumors of cancer patients are T cells with the potential to detect and eliminate tumor cells. Although the T cells themselves are functionally impaired, their T cell receptors (TCRs) are still able to recognize antigens on cancer cells. If these TCRs are transferred into non-impaired T cells from the patient’s bloodstream, they can redirect those T cells to recognize and kill cancer cells. Some of the T cells in a tumor recognize patient-specific neoantigens and thus are only able to kill that patient’s cancer cells. Other T cells, however, recognize targets that are common to many patients (i.e., shared antigens), and their TCRs may be developed as therapeutics that are broadly applicable across many patients. The TScan Discovery Platform is designed to identify TCRs from patient tumors that recognize shared antigens and to discover the natural targets of these TCRs. By processing tens of thousands of patient-derived TCRs in this way, TScan is progressively building a repository of therapeutically active TCRs with novel targets that can ultimately be used to treat a wide variety of patients with diverse tumor types.